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Abstract. The WAP four-disulfide core domain protein 2 
(WFDC2) is frequently overexpressed in epithelial ovarian 
cancer cells and has been proposed as a potential biomarker. 
The biological function of WFDC2 in tumor progression 
remains unclear. In this study, the stable expression of short 
hairpin RNA (shRNA) against WFDC2 in the human ovarian 
SKOV3 cell line was established. Cell proliferation in vitro 
was determined by MTT assay. Cell cycle and apoptosis 
were analyzed by FACS. The expression of genes related to 
cell proliferation and survival was detected by real-time 
RT-PCR and western blotting. In vivo tumor growth assay was 
performed by establishing WFDC2-knockdown xenografts 
in nude mice and monitoring tumor growth. The expression 
of WFDC2, Ki67 and activated caspase-3 was analyzed 
by immunohistochemistry in order to determine the role of 
WFDC2 in proliferation and apoptosis. Our results revealed 
that the silencing of WFDC2 abolished ovarian cancer cell 
proliferation, suppressing tumor formation and growth in 
ovarian cancer cells both in vitro and in vivo. The knockdown 
of WFDC2 induced upregulation of Fasl and the downregula-
tion of cyclin D1 activated caspase-3 and Ki67. These results 
indicate that WFDC2 plays a crucial role in tumor formation 
and growth in ovarian cancer cells. WFDC2 may be a poten-
tial therapeutic target for epithelial ovarian cancer.
Introduction
Ovarian cancer is one of the most common cancers among 
women, and it is the leading cause of mortality among gyne-
cological malignancies worldwide. WAP four-disulfide core 
domain protein 2 (WFDC2) was first identified in the epithe-
lium of the distal epididymis and was originally predicted 
as a protease inhibitor involved in sperm maturation. Recent 
interest in WFDC2 has been generated by the consistent 
demonstration of its overexpression in ovarian carcinomas 
in comparison to normal ovarian tissue (1-3). This gene, also 
known as human epididymis 4 (HE4), has been consistently 
identified as being upregulated in ovarian carcinoma by gene 
expression profiling studies and has been proposed as a puta-
tive serum biomarker for malignant ovarian masses (1,4-6).
The WFDC2 gene is located on human chromosome 20q12-
13.1. The amplification of 20q12-13 has been demonstrated 
specifically in breast and ovarian carcinomas (2,7). Fourteen 
genes which encode proteins with a WAP-type four-disulfide 
core (WFDC) domain have been identified on this region. Two 
of these genes, SLPI and p13, encoded as antileukoproteinase 1 
and elafin, which are co-expressed with WFDC2 play a role in 
the development or progression of various types of carcinomas 
(8,9). This led us to investigate whether WFDC2, a member of 
the WAP cluster, overexpressed in ovarian cancer, may also be 
involved with this disease. 
The most studied WAP proteins, p13 and SLPI, both 
identified as serine-proteinase inhibitors, are reported to be 
associated with aggressive, high-risk, or metastatic cancer 
originating from various organs (10,11). The expression of 
SLPI was positively correlated with the increased expres-
sion of the cell cycle progression factor, cyclin D1, and its 
causal role in the promotion of malignant behavior was also 
demonstrated in lung carcinomous cells stably transfected 
with human SLPI-expression constructs (8,12-14). Elafin was 
reported to be overexpressed in late-stage, high-grade serous 
ovarian carcinomas and to correlate with poor overall survival 
(15). In breast cancer cells and tissue, elafin was found to 
protect cyclin E from proteolysis with elastase, thus regulating 
cell cycle progression (16). Both SLPI and elafin may regulate 
WAP four-disulfide core domain protein 2 mediates the 
proliferation of human ovarian cancer cells through the 
regulation of growth- and apoptosis-associated genes
YAO CHEN1,  XIA MU2,  SUIHAI WANG1,  LIANG ZHAO3,  YINGSONG WU1,  JILIANG LI1,4  and  MING LI1
1School of Biotechnology, Southern Medical University, Guangzhou 510515;  2Guizhou Provincial People's Hospital,  
Guiyang, Guizhou 550002;  3Department of Pathology, School of Basic Medical Sciences, Southern Medical University, 
 Guangzhou 510515, P.R. China;  4Cancer Research UK (CRUK) Molecular Oncology Laboratories, Department of Oncology, 
Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK
Received July 23, 2012;  Accepted September 28, 2012
DOI: 10.3892/or.2012.2114
Correspondence to: Dr Ming Li, School of Biotechnology, 
Southern Medical University, Guangzhou 510515, P.R. China
E-mail: mingli2006_2006@126.com
Dr Jiliang Li, Cancer Research UK (CRUK) Molecular Oncology 
Laboratories, Department of Oncology, Weatherall Institute of 
Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK
E-mail: ji-liang.li@imm.ox.ac.uk
Key words: WAP four-disulfide core domain protein 2, ovarian 
cancer, cell proliferation, apoptosis
CHEN et al:  WFDC2 INDUCES TUMOR FORMATION IN OVARIAN CANCER 289
NF-κB activity induced by inflammatory cytokines; their 
tumor proliferation promotion and spread may be involved in 
the regulation of NF-κB activity (17,18).
Although, no antiproteinase-inhibitory activity has been 
assigned to WFDC2 and the biological role of WFDC2 
remains unclear, on the basis of the similarity to SLPI and 
p13, we hypothesized that WFDC2 has a pro-cancer function 
in ovarian cancer by regulating tumor proliferation and facili-
tating tumor spread through a tissue remodeling method. To 
explore the functional role of WFDC2 in ovarian cancer, we 
performed the transfection of SKOV3 cells with short hairpin 
RNA (shRNA) against WFDC2 and investigated the effect of 
WFDC2 silencing on cell proliferation, tumorigenesis, cell 
cycle and apoptosis.
Materials and methods 
Materials and animals. Reagents, enzymes and laboratory 
supplies were purchased from the following vendors: restric-
tion enzymes from Takara; MTT from Sigma (Shanghai, 
China); G418 (neomycin) and TRIzol reagent from Invitrogen 
Life Technologies; cell culture media, antibiotics/serum and 
glutamine from Gibco-BRL. All other molecular reagents and 
solvents, when not listed, were purchased from Sigma. All other 
reagents were of molecular or imaging grade. 6- to 8-week-
old female BALB/c-nu mice used in these experiments were 
purchased from the Experimental Animal Center of Southern 
Medical University (P.R. China) and were maintained under 
standard pathogen-free conditions.
Gene silencing. SKOV3, human ovarian carcinoma cells, were 
selected for these experiments. Four different WFDC2-specific 
target sequences were designed and constructed using the 
WFDC2 reference sequence (Gene Bank Accession 
no. NM_0006103.3). The target sequences of WFDC2-209, 
WFDC2-216, WFDC2-308 and WFDC2-318 are homologous 
to 5'-GCTCTCTGCCCAATGATAAGG3', 5'GCCCAAT 
GATAAGGAGGGTTC3', 5'GTGTCCTGGCCAGATG 
AAATG-3' and 5'-GATGAAATGCTGCCGCAATGG-3' of 
the WFDC2-specific mRNA, respectively, with an invalid 
RNAi sequence of 5'-GTTCTCCGAACGTGTCACGT-3' as 
the negative control. The shRNAs were chemically synthe-
sized and the shRNA expression vector (WFDC2-pGPU6/
Neo) was constructed by Shanghai Genepharma Co., Ltd. The 
correct insertion of the specific shRNA was further confirmed 
by sequencing. The SKOV3 cell line was transfected with 
WFDC2-specific shRNA-encoding expression vectors using 
Lipofectamine 2000 (Invitrogen Life Technologies). For stable 
silencing of WFDC2, the transfected SKOV3 cell line was 
selected by G418. The G418-resistant colonies were selected, 
expanded and analyzed separately.
In vitro cell proliferation assay. In vitro proliferation assay was 
performed using the MTT assay following the manufacturer's 
instructions (Sigma). Cells were incubated at 500 cells/well in 
96-well plates in triplicates and cultured in complete DMEM/F12 
medium (10% FBS) to observe the growth rate. For 6 days, the 
absorbance of the cells was measured using the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method, 
and the cell growth curves were calculated.
Colony formation assay. Cells were planted in 24-well plastic 
plates spread with low-melting point agar (0.35% in the upper 
layer and 0.6% in the lower layer). Each type of cell was planted 
in 5 wells, with 100 cells/well. The cells were cultured at 37˚C 
with 5% CO2 and under saturation humidity for 14 days. Cell 
colonies consisting of more than 50 cells were counted under 
an inverted microscope. The colony formation rate was calcu-
lated as follows.
   average number of colonies of 5 wells
Colony efficiency = ------------------------------------------------------------------   x 100%
             number of plated cells
RNA extraction and real-time RT-PCR. Total RNA was 
isolated following the manufacturer's instructions (PrimeScript 
1st Strand cDNA Synthesis kit, Takara). Reverse transcription 
was also performed following the manufacturer's instructions 
in a total volume of 20 µl using an Oligo(dT) primer and 1 µg 
of total RNA. Each primer set was designed to flank an intron 
to prevent the amplification of genomic DNA, using Primer 
Express 3.0. The forward and reverse primers, respectively, 
are shown in Table I. β-actin was used to evaluate the effi-
ciency and variability of the reverse transcription step. cDNA 
samples (0.1 µg) were amplified using the SYBR-Green PCR 
Master Mix (Takara) under conditions recommended by the 
manufacturer: i) pre-incubation at 95˚C for 30 sec; ii) 40 PCR 
cycles of 95˚C for 5 sec, 55˚C for 30 sec and 72˚C for 34 sec. 
Samples were assayed in duplicate using the ABI Prism 7500 
detection system (Perkin Elmer Applied Biosystems). Relative 
quantification was then calculated by subtracting the average 
CT from the corresponding average CT for β-actin.
Western blot analysis. Cells were harvested and lysed in 
ice-cold lysis buffer [10 mM HEPES (pH 7.9), 150 mM 
NaCl; 1 mM EDTA]. Proteins were fractionated on 
SDS-polyacrylamide gels and transferred to a nitrocellu-
lose membrane. Immunoblotting was performed with goat 
polyclonal anti-human WFDC2 (Santa Cruz Biotechnology, 
Inc.), goat polyclonal anti-human P21, goat polyclonal anti-
human Rb, goat polyclonal anti-human Bcl2, goat polyclonal 
anti-human Bax, goat polyclonal anti-human cyclin D1, goat 
polyclonal anti-human CDK4 and goat polyclonal anti-human 
activated caspase-3 antibodies (Cell Signaling Technology, 
Inc.). Anti-goat secondary antibody conjugated to horseradish 
peroxidase (Santa Cruz Biotechnology, Inc.) was used to visu-
alize the stained bands with an enhanced chemiluminescence 
(ECL) visualization kit (Amersham). 
Flow cytometry. Cells were trypsinized and washed with 
phosphate-buffered saline (PBS). The cells were incubated 
in 4% paraformaldehyde and fixed at 4˚C for 30 min. After 
washing 3 times, cells were digested with 1% RNase at 37˚C 
for 30 min and stained with 50 µg/ml propidium iodide (PI; 
Sigma, Shanghai, China) for 1 h at 4˚C for cell apoptosis and 
cycling assay. The results were analyzed using WinMDI soft-
ware and 10,000 events for each sample were collected. Cell 
suspensions were incubated with antibodies to Fas and Fasl 
(1 µg/1x106 cells) for 30 min at 37˚C, washed 3 times with 
PBS and incubated with PE- and FITC-labeled secondary 
antibodies for 30 min at 37˚C. The expression of Fas and 
Fasl/10,000 cells was determined by flow cytometry.
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Xenograft formation. The animal study was divided into 
two parts. Firstly, 10 mice were divided into 2 groups and, 
SKOV3-209 and SKOV3-NA cells (1x106) were injected into 
the flank of 6- to 8-week-old female BALB/c-nu mice, respec-
tively. The SKOV3-209 and SKOV3-NA xenografts were 
excised at 6 weeks. The tumor volume (V) was calculated as 
V = W x W x L x 0.52. Secondly, the tumor volume (V) was 
measured at different time points by using a caliper. The tumor 
volume (V) was calculated as V = W x W x L x 0.52 and the 
xenografts were harvested for subsequent analysis by being 
fixed in buffered neutral formalin when reaching ~200 mm3.
Immunohistochemistry. Immunohistochemistry was per-
formed using 8-to 10-µm serial sections of fixed tissue placed 
onto positively charged glass slides using a single-staining 
procedure. The protocols used with each antibody are provided 
below.
Anti-WFDC2 monoclonal, anti-Ki67 rabbit polyclonal 
and anti-activated caspase-3 rabbit polyclonal antibodies were 
applied to the slides at a dilution of 1:2,000 and incubated 
overnight at 4˚C. The slides were then stained using the avidin-
biotin method, as described above. 3,3'-Diaminobenzidine 
chromogen was used to develop a brown color for 5 min. 
Slides were lightly counterstained with hematoxylin. Tumor 
cells were considered positive for the antigen when there was 
brown colored staining. The intensity of WFDC2 immunos-
taining of the xenografts was scored as negative (0), weak (1), 
medium (2) and strong (3). The extent of staining, defined as the 
percentage of positive-stained cells, was scored as 1 (≤10%), 
2 (11-50%), 3 (51-75%) and 4 (>75%). An overall expression 
score, ranging from 0 to 12, was calculated by multiplying the 
score of the staining intensity and the score of the extent of 
staining. The final staining score was presented as the negative 
(overall score of 0), 1+ (overall score of 0-3), 2+ (overall score of 
4) or 3+ (overall score of ≥5). 
Ki67 is located in the cell nucleus. At least 500 tumor 
cell nuclei for each xenograft (n=5) of the SKOV3-209 or 
SKOV3-NA groups were randomly selected and examined. 
The number of Ki67-positive tumor cell nuclei was counted 
and the Ki67-positive index was calculated as follows: Ki67 
index = (number of apoptotic cells/total cell number) x 100%.
Statistical analysis. Microsoft Office Excel 2007 and the 
statistical software SPSS 13.0 were used in data processing and 
in analyzing statistical significance with one-way ANOVA. 
P-values <0.05 were considered to indicate a significant differ-
ence. Data are expressed as the means ± SD from at least 
3 independent experiments.
Results
WFDC2 gene silencing. shRNA targeting WFDC2 was used 
to knockdown the WFDC2 expression in SKOV3 cells. The 
silencing efficiency was detected by real-time quantitative PCR 
and western blotting. shRNA reduced the WFDC2 expression 
in both the SKOV3-209 and -309 sublines (Fig. 1). The shRNA 
targeting sequence 309 and 209 decreased WFDC2 mRNA by 
up to 73.1 and 86.3%, respectively (Fig. 1). The transfection of 
shRNA 209 induced a significant downregulation of WFDC2 
expression in all shRNA clones. Therefore, the stable cell line 
SKOV3-209 was selected for subsequent analysis. Cells trans-
fected with an invalid RNAi sequence, namely SKOV3-NA, 
were used as the negative control.
Table I. Primers for real-time RT-PCR assay.
Primers 5'→3' Annealing
  Tmp (˚C)
Apaf-1 F: ACAATGCTCTACTACATGAAGGATATAAAGA 58
 R: CACTGGAAGAAGAGACAACAGGAA 
BCL2L11 F: ATCCCCGCTTTTCATCTTTA 58
 R: AGGACTTGGGGTTTGTGTTG 
Bax F: GCTGTTGGGCTGGATCCAAG 55
 R: TCAGCCCATCTTCTTCCAGA 
BCL-X F: CATGGCAGCAGTAAAGCAAG 57
 R: TAGAGTTCCACAAAAGTATC  
Cyclin D1 F: CGCCCCACCCCTCCAG    56.8
 R: CCGCCCAGACCCTCAGACT 
Cyclin E1 F: TCCAGGAAGAGGAAGGCAAAC 60
 R: CCTGTCGATTTTGGCCATTT 
Casp3 F: GAGTGCTCGCAGCTCATACCT 59
 R: CCTCACGGCCTGGGATTT 
Casp7 F: GAAGCCCTCTGCTCCATCC 58
 R: GGCAACTCTGTCATTCACCCT 
Casp9 F: GGGTCGCTAATGCTGTTTCG 56
 R: TGCAAGATAAGGCAGGGTGAG 
gadd45a F: TCAGCGCACGATCACTGTC 58
 R: CCAGCAGGCACAACACCAC 
RB F: ACTCCGTTTTCATGCAGAGACTAA 57
 R: GAGGAATGTGAGGTATTGGTGACA 
TP53BP2 F: GGATGGGTATGATGGGACAG 60
 R: GGGCCAAATATTCAGAAGC 
P73 F: GGATTCCAGCATGGACGTCTT 58
 R: GCGCGGCTGCTCATCT 
P21 F: TGGACCTGTCACTGTCTTGTACC       57.5
 R: CTTCCTGTGGGCGGATTAG 
P53 F: TCTGACTGTACCACCATCCACTAC 58
 R: CAGGCACAAACACGCAC 
P73 F: CATGGAGACGAGGACACGTACTA 60
 R: CCATCAGCTCCAGGCTCTCT 
KI67 F: GAGTGCCTGCTCAGTGTTGG 60
 R: GCCACACTGTGTCGTCGTTT 
AKT1 F: TCCGAGCTGTTCTTCCACC 59
 R: CTTGATCCCCTCCTTGCAC  
CD44 F: TTTGCATTGCAGTCAACAGTC 60
 R: GTTACACCCCAATCTTCATGTCCAC 
Fas F: ACACTGTGACCCTTGCACCAA 60
 R: AGCCACCCCAAGTTAGATCTG 
FasL F: GGCCTGTGTCTCCTTGTGAT 56
 R: TGCCAGCTCCTTCTGTAGGT 
β-actin F: TTGTTACAGGAAGTCGCTTGCC 60
 R: ATGCTATCACCT CCCCTGTGTG 
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Knockdown of WFDC2 expression inhibits cell growth in vitro. 
MTT assay and colony formation assays were conducted to 
determine the cell growth. The growth curves indicated that 
the growth rates did not have marked differences among the 
SKOV3-209, SKOV3-NA and SKOV3 cells on the first day 
after transfection (Fig. 2A). However, on each day for the 
following five days, the growth rate was significantly lower in 
SKOV3-209 cells compared to that in SKOV3-NA and SKOV3 
cells (Fig. 2A). Six days after plating, the cell density observed 
for the control line was nearly 1.5-fold higher compared to that 
of the WFDC2 shRNA-transfected subline. The average colony 
formation rate in SKOV3-NA was 62.4±4.08%. After being 
transfected with shRNA, the average colony formation rate of 
SKOV3-209 cells was 37.4±2.97%, with an inhibition rate of 
39.98%. These results indicate a positive correlation between 
WFDC2 expression and ovarian cancer cell growth (Fig. 2B). 
Genes related to cell proliferation and survival were modified 
by WFDC2 knockdown. To determine the effect of WFDC2 
knockdown on SKOV3 cell proliferation and survival, the 
mRNA levels for a number of genes related to cell proliferation 
and survival were detected in the shRNA-silenced lines and, for 
comparison, in the SKOV3-NA cell line by real-time RT-PCR. 
When normalized to the expression of the control β-actin gene, 
which was unaffected by cellular WFDC2 expression, a slight 
decrease in cyclin D1, cyclin E, p21, caspase-3 and Bcl2 expres-
sion was observed at the mRNA level in SKOV3-209 cells 
(Fig. 3A). However, Fasl was increased approximately 8-fold 
(Fig. 3A). We also evaluated the expression of these genes at 
the protein level. According to western blot results, the down-
regulation of cyclin D1 and activated caspase-3 expression was 
also observed at the protein level, while no difference in the 
expression of other cell cycle- and apoptosis-related genes was 
detected by western blotting (Fig. 3B-D). 
Fas/Fasl is a membrane protein related to cell apoptosis. 
As a primary membrane receptor, we used flow cytometry to 
assess the expression of Fas/Fasl. The results indicated that the 
expression of Fasl was upregulated by WFDC2 knockdown 
while no change was observed in Fas (Fig. 3E). WFDC2 
knockdown affected the expression of cyclin D1, caspase-3 
and Fasl which are related to the proliferation and apoptosis 
of tumor cells.
WFDC2 knockdown arrests the cell cycle but has little effect on 
cell apoptosis. To investigate the potential function of WFDC2 
in the proliferation and survival of ovarian cancer cells, the 
cell cycle and apoptosis of SKOV3 cells were assessed by flow 
cytometry. The percentage of SKOV3-209 and SKOV3-NA 
cells in the G0/G1 phase was 79.38±3.08 and 63.1±2.03%, 
respectively. The percentage of cells in the S phase for these 
two groups was 18.47±2.06 and 39.82±1.89%, respectively 
(Fig. 4A and B). These results indicated that a significant 
percentage of SKOV3 cells was arrested in the G0/G1 phase 
after treatment with WFDC2 shRNA. The apoptosis rate 
was also examined by flow cytometry. Although western 
blot and flow cytometry results demonstrated that activated 
caspase-3 and Fasl expression was significantly decreased or 
increased, respectively in the SKOV3-209 cells, the apoptosis 
Figure 1. Expression of WFDC2 in WFDC2-silenced clonal lines. (A) Western blot analysis of the expression of WFDC2 and GAPDH. (B) Normalized 
WFDC2 protein levels in the shRNA-transfected, mock-transfected NA and the control. The relative quantities of WFDC2 protein were determined by 
densitometry and normalized using GAPDH. *P<0.05 compared to SKOV3-NA; #P<0.05 compared to SKOV3.
Figure 2. Knockdown of WFDC2 expression inhibits cell growth in vitro. (A) Proliferation curve of SKOV3 cells treated with an empty vector control (SKOV3-NA) 
and WFDC2 knockdown (SKOV3-209) or PBS (SKOV3) over 6 days measured by MTT assay. *P<0.05 compared to SKOV3-NA; #P<0.05 compared to SKOV3. 
(B) Histogram plots represent the number of colonies at day 6 in 3 separate experiments performed in triplicate. Data presented in A and B (means ± SE) are from 
3 independent experiments, with each experiment performed in triplicate. *P<0.05 compared to SKOV3-NA; #P<0.05 compared to SKOV3.
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rate displayed no significant change between SKOV3-209 and 
SKOV3-NA cells in vitro. No difference was observed between 
the WFDC2 knockdown cells and the negative control cells 
in vitro (data not shown).
WFDC2 is required for SKOV3 cell tumorigenesis. To inves-
tigate the effect of WFDC2 knockdown on tumorigenesis in vivo, 
an ovarian carcinoma xenograft model was established. The 
short time course of tumor formation minimized confounding 
effects related to the possible loss of WFDC2 expression in 
mice. SKOV3-NA and SKOV3-209 cells were injected into the 
groin of nude mice. In mice injected with cells containing an 
inducible clone of shRNA WFDC2, tumor growth was delayed 
for several days after the induction of shRNA and tumor sizes 
were statistically different at every measurement time point 
after Day 18 (Fig. 5A). Loss of WFDC2 expression resulted in a 
significant delay in tumor growth, where the difference in tumor 
Figure 3. Genes related to cell proliferation and survival are modified by WFDC2 knockdown. (A) Normalized cell cycle- and apoptosis-related gene mRNA 
levels in the SKOV3-NA and SKOV3-209 cell lines. The relative quantities of the WFDC2 protein were determined by densitometry and normalized using 
β-actin. *P<0.05 compared to SKOV3-NA. (B) Western blot analysis of the expression of cell cycle- and apoptosis related-genes and GAPDH. (C) Normalized 
cyclin D1 protein level in the SKOV3-NA and SKOV3-209 cell lines with GAPDH. *P<0.05 compared to SKOV3-NA. (D) Normalized activated caspase-3 
protein level in the SKOV3-NA and SKOV3-209 cell lines with GAPDH. *P<0.05 compared to SKOV3-NA. (E) The percentage of Fas/Fasl-positive cells 
detected by flow cytometry. *P<0.05 compared to SKOV3-NA. 
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volume was statistically significant after 6 weeks (Fig. 5B). To 
explore the mechanisms of tumor inhibition in vivo the animals 
were sacrificed when the tumor volume was ~200 mm3. 
Analysis of WFDC2 protein expression by immunohistochem-
istry confirmed a reduced cytoplasmic and secreted expression 
in SKOV3-209 mice after six weeks. The average tumor volume 
was 8.9-fold larger in the SKOV3-NA group compared to that in 
the SKOV3-209 group (P<0.05) (Fig. 5B). 
Cell proliferation and apoptosis were also observed 
in vivo through a tumorigenesis assay. The Ki67 protein is 
present during all active phases of the cell cycle (G1, S, G2 
and mitosis), but is absent from resting cells (G0), making it 
an excellent marker for determining the cell cycle ratio. The 
fraction of Ki67-positive tumor cells is often correlated with 
the clinical course of cancer. Therefore, Ki67 is an important 
indicator of tumor proliferation in vivo. In our study, with 
WFDC2 knockdown (Fig. 5C), Ki67 staining demonstrated 
that nuclear localization of the protein was reduced when 
WFDC2 was downregulated (Fig. 5C). These results confirm 
the relationship between the WFDC2 and cell cycle of cancer 
cells.
In SKOV3-209 xenografts, we noted the presence of acti-
vated caspase-3 in the nucleus of the tumor cells, which was 
almost absent in the SKOV3-NA controls (Fig. 5D). However, 
the activated caspase-3-positive cells were in a limited propor-
tion of the total cells. Our results suggest that further studies 
are required to determine the relationship between apoptosis 
and WFDC2.
Discussion
Genomic analysis of ovarian cancer identified amplifica-
tion of WFDC2 and the whey acidic protein locus in a large 
proportion of epithelial ovarian cancers (1,4,6,9,11). WFDC2 
demonstrates a tumor-restricted, upregulated pattern of 
expression, making it a potential marker (3,5,7). 
WFDC2 contains two WAP structural domains and belongs 
to the WAP protein family. Previous research indicates that 
proteins with a WFDC motif usually exhibit the following: A 
number of WAP proteins have been mapped to human chromo-
some 20q12-13.1, a region amplified in several types of cancers 
leading to the proposal that genes located on this region of chro-
mosome 20 play a role in carcinogenesis and tumor progression 
(6,9); exhibit anti-inflammatory and antimicrobial activity 
against Gram-negative bacteria and viruses by regulating the 
NF-κB activity (17-19); regulate cell growth (13,14,20,21) and 
regulate angiogenesis and cell spread by the interference of the 
leucocyte cell-derived and tumor cell-derived proteinase and 
cytokines (8,12,22,23). Despite these findings the precise func-
tion of WFDC2 remains unknown.
In this study, we constructed a WFDC2 shRNA expression 
plasmid, which achieved efficient and specific WFDC2 gene 
silencing in the human ovarian cancer cell line SKOV3. With 
WFDC2 gene silencing, we studied the function of WFDC2 
in cancer cell growth and survival. To examine whether the 
modulation of WFDC2 expression influences the tumorigenic 
properties of ovarian cancer cells, we examined SKOV3 cell 
proliferation and apoptosis in vitro. As demonstrated by both 
the MTT assay and FACS analysis, loss of WFDC2 expression 
resulted in a significant delay in tumor growth in vitro and the 
cell cycle was arrested in the G0/G1 phase. Furthermore, the 
injection of SKOV3-NA and SKOV3-209 cells into nude mice 
demonstrated that in vivo silencing of WFDC2 expression in 
ovarian cancer cells suppressed tumor growth. According to 
these results, WFDC2 may play an oncogenic role in ovarian 
cancer progression through promoting cell proliferation.
Figure 4. WFDC2 knockdown arrests the cell cycle but has little effect on cell apoptosis. (A) Flow cytometry graphs for SKOV3-NA and SKOV3-209 cell lines. 
(B) Quantification of the percentages of cells in the G0/G1 and S phases. *P<0.05 compared to SKOV3-NA. 
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In order to further study the role of WFDC2 in tumor 
growth, we studied the correlation between WFDC2 and 
a series of genes related to cell proliferation and survival. 
Noteworthy is the identification of cyclin D1 as a downstream 
target of WFDC2. The ability of WFDC2 to induce cyclin D1 
expression occurred at the levels of transcription and its 
expression was highly specific. This is also evident from the 
cell cycle of SKOV3 cells; WFDC2 gene silencing arrested 
the cell cycle in the G0/G1 phase. Cyclin D1 belongs to the 
core cell cycle machinery and it is frequently overexpressed 
in human cancers (13,24,25). The strong positive correlation 
between WFDC2 and cyclin D1 expression observed in our 
study suggests that WFDC2 may be linked to the develop-
ment and progression of ovarian cancer by regulating the cell 
cycle of ovarian cancer cells. Noteworthy, when WFDC2 was 
downregulated, nuclear localization of the Ki67 was reduced 
significantly in the xenografts. Ki67 is a nuclear protein that 
is necessary for cellular proliferation. The fraction of Ki67-
Figure 5. WFDC2 is required for SKOV3 cell tumorigenesis. (A) Mean tumor growth curves for SKOV3-209 and SKOV3-NA xenografts. *P<0.05 compared 
to SKOV3-NA. (B) Mean tumor volumes for SKOV3-209 and SKOV3-NA xenografts at 6 weeks. (C) Immunohistochemistry for WFDC2, Ki67 and activated 
caspase-3 in SKOV3-209 and SKOV3-NA xenografts. (D) Normalized WFDC2 and Ki67 protein levels in SKOV3-209 and SKOV3-NA xenografts. *P<0.05 
compared to SKOV3-NA.
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positive tumor cells is often correlated with the clinical course 
of cancer, which makes it an excellent marker to determine the 
growth fraction of a given cell population in tumorigenicity 
(26-29). The positive correlation between WFDC2 and Ki67 
may indicate the positive role of WFDC2 in tumor growth. 
Based on the combination of in vivo and in vitro experimental 
results, WFDC2 possibly plays an active role as a facilitator 
through regulation of cyclin D1 and Ki67 expression in tumor 
cell proliferation.
We also studied and analyzed the relationship between 
WFDC2 and apoptosis-related genes. In WFDC2 knockdown 
cells, a series of apoptosis-related gene expression levels 
were altered (30,31). Fasl is an important apoptosis-related 
membrane protein and enhanced Fasl expression at mRNA 
and protein level caused by WFDC2 knockdown cells indi-
cates that SKOV3-209 may more easily undergo apoptosis. 
However, in the in vitro flow cytometry experiments, WFDC2 
gene knockdown did not lead to changes in the apoptosis 
rate of SKOV3 cells. The activation of caspase-3 levels was 
lower in the SKOV3-209 cells compared to the control group 
as demonstrated from the results of western blot analysis. 
In vivo, the activation of caspase-3 was very weak in both the 
WFDC2-knockdown and the control groups; the expression 
level in the knockout group was observed to be slightly higher.
Since these experimental results are contradictory, the 
role of WFDC2 in apoptosis remains unclear. In our experi-
ments, SKOV3 cell apoptosis rate compared to only 2-5%, the 
expression of apoptosis-related indicators, Fasl and activated 
caspase-3, in SKOV3 cells was low; thus further analysis is 
required to determine the relationship of WFDC2 and tumor 
cell apoptosis in different cell lines and clinical specimens.
In summary, the generation and subsequent use of a WFDC2 
‘knockdown’ model has allowed for the initial elucidation of 
the molecular mechanism behind WFDC2 overexpression and 
tumor progession. In this study, we speculated and validated 
the association between cancer and WFDC2 and analyzed 
the potential role of WFDC2 in tumor progression. Our data 
suggest that WFDC2 is a proliferation inducer both in vitro 
and in vivo. The positive correlation between the expression 
of WFDC2 with cyclin D1 and Ki67 and the negative correla-
tion with FasL was demonstrated. The cellular and molecular 
evidence demonstrates the promoting effect of WFDC2 in 
human ovarian cancer cell growth and tumorigenicity. These 
results strongly suggest the possible involvement of WFDC2 
expression in tumor progression.
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